about
The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug developmentA phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies.A phase I trial of SJG-136 (NSC#694501) in advanced solid tumorsEffect of drug transporter genotypes on pravastatin disposition in European- and African-American participantsThymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancersEthnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition.Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomibPolymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry.PSMB9 codon 60 polymorphisms have no impact on the activity of the immunoproteasome catalytic subunit B1i expressed in multiple types of solid cancerPhase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors.Statistical methods for assays with limits of detection: Serum bile acid as a differentiator between patients with normal colons, adenomas, and colorectal cancer.Transporters and renal drug elimination.Activity-based near-infrared fluorescent probe for LMP7: a chemical proteomics tool for the immunoproteasome in living cells.Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.Overexpression of OATP1B3 confers apoptotic resistance in colon cancer.Inhibitors of the immunoproteasome: current status and future directionsThe immunoproteasome: an emerging therapeutic target.Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-α: impact on gastrointestinal cancers driven by secondary bile acids.Role of hypoxia inducible factor-1α in the regulation of the cancer-specific variant of organic anion transporting polypeptide 1B3 (OATP1B3), in colon and pancreatic cancer.Lack of critical involvement of endothelial nitric oxide synthase in vascular nitrate tolerance in mice.eNOS-dependent vascular interaction between nitric oxide and calcitonin gene-related peptide in mice: gender selectivity and effects on blood aggregation.Mechanism-based partial inactivation of glutathione S-transferases by nitroglycerin: tyrosine nitration vs sulfhydryl oxidation.Hepatic uptake of the novel antifungal agent caspofungin.Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors.Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growthDifferential interactions of nitric oxide donors with rat oxyhemoglobinA common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expressionDetermination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation studyPhase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumorsNext-generation proteasome inhibitors for cancer therapyConnectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer
P50
Q28201907-A6502B0D-A47D-4763-9069-CFD15BD3D286Q28234990-0FB34332-A2FC-4474-9729-0B7ED57E040AQ30411680-3EE9A1E9-C3EC-4A87-8CC2-36B58C3BD28AQ33385770-AB5F4541-C90C-4AA7-96D3-769C4A458644Q33776950-AE70B645-3BF8-43EF-BB32-CE2543B31A64Q34214957-3503C0C1-9941-4DB2-955F-27E8E59B5563Q34281819-A7A48176-774A-4557-9AC3-4906C374B925Q34317307-E9AE53AB-AFCC-4B5A-B227-B3947BD8EB0DQ34381625-FAE8AE3F-FB64-40F4-9819-92C3640B13B6Q34989194-C69C0B7B-99B7-4D1C-8211-3AC8588EF1B9Q35024036-DBE0A583-0F14-4B6E-88B2-015698048975Q35064947-5E15BD3A-78DA-4CB0-9609-1BDE5DF52743Q35639118-3195812B-0B5D-4832-8532-378C49A267FAQ36201624-F2785F2F-3454-4027-BF37-2EB94F3808C1Q36300784-8094E7F5-B8B1-4363-906A-0E118FBD3258Q37020822-401EFF9A-BFAB-4B4E-8978-B972DEDC6652Q37292307-CAE44720-8E4C-4B3F-A669-4AFAF29C400AQ37913443-34F40B2F-26BF-4176-A434-5134DD1D5454Q38615458-5FEA4463-B68D-4347-B7BE-394162CF161DQ39113927-91CDA2B9-AA76-463F-A36E-32BACEC3F83FQ42124934-C1D23F8F-10A9-4F61-B7D9-40909BF1D12DQ44277687-DBA1CE77-0308-4E71-909E-46ACCDCE1EBFQ44349331-5AD3EF45-67C6-4A6F-9F26-905621742294Q45269887-C1BFE483-F4D7-4BDB-B4F1-6CC74BF015E2Q51210425-94842F94-ED32-4B16-9F3F-DA8E5A04F285Q55041963-2C2B07B3-0632-418F-9732-5752DD4D5409Q64110173-2AC95ADC-7006-47FF-9452-F7F431C55AB7Q78020865-4045408A-900B-4AD9-8E76-C654115A7615Q80370235-0CD7D002-E6D3-47DC-8251-B093229B943DQ80758638-67633301-9597-47C1-ACCD-8CFEDA7379FEQ84918578-55C4D573-A0CE-4563-8599-886F37FEAC81Q88357671-F7CAFD31-E7F6-4D70-B7D5-71E63D2EF42AQ94595614-2157B85F-39A1-4B9A-839C-C32F9D5E2BE9
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Wooin Lee
@ast
Wooin Lee
@en
Wooin Lee
@es
Wooin Lee
@nl
Wooin Lee
@sl
type
label
Wooin Lee
@ast
Wooin Lee
@en
Wooin Lee
@es
Wooin Lee
@nl
Wooin Lee
@sl
prefLabel
Wooin Lee
@ast
Wooin Lee
@en
Wooin Lee
@es
Wooin Lee
@nl
Wooin Lee
@sl
P1053
K-7789-2012
P106
P1153
56164990100
56195044000
P31
P3829
P496
0000-0001-7805-869X